CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2010-12-22): Erythromycin improves visibility during endoscopy for variceal bleeding

Clinical

Erythromycin improves visibility during endoscopy for variceal bleeding

Last Updated: 2010-12-22 9:00:30 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Band ligation of bleeding esophageal varices can be impossible when blood obscures the endoscopic view - but giving erythromycin before the procedure will clear the visual field, according to randomized trial results from Saudi Arabia.

Not only does erythromycin pretreatment improve visibility, but it also raises the likelihood of bleeding control by band ligation and shortens patients' hospital stay, according to Dr. Ibrahim H. Altraif and associates at the King Abdul-Aziz Medical City in Riyadh.

Intravenous erythromycin, a potent motilin agonist, induces rapid gastric emptying that lasts for at least two hours, the authors say in their paper, published online December 9th in Gastrointestinal Endoscopy.

Their study involved 90 patients with cirrhosis who had been vomiting blood due to variceal bleeding during the previous 12 hours. The 47 patients randomized to the intervention group received an intravenous bolus infusion of 125 mg erythromycin lactobionate in 50 mL normal saline. The other 43 patients received only the saline. (All patients also received octreotide, esmoprazole, and ceftriaxone.)

"The erythromycin infusion has to be given over 10 minutes (i.e., not fast)," Dr. Altraif cautioned in an email to Reuters Health.

Endoscopies began 30 minutes after the erythromycin infusions were completed. Hepatologists assessed gastric cleansing on a scale of 1 to 16, where a score of at least 15 indicated a clear esophagus and stomach. More patients in the erythromycin group got a score of 15 or 16 (49% vs 23%, p < 0.01); the mean scores were 12.5 with erythromycin and 9.8 with saline (p < 0.01).

In fact, on multivariate analysis, erythromycin was the only predictor of an empty stomach.

As a result, the average time needed for endoscopy was also shorter after erythromycin (19 vs 26 min, p < 0.005). The physicians found that with erythromycin, they could control bleeding by band ligation more often (70% vs 49%, p < 0.04) and that hospital stays were shorter (3.4 vs 5.1 days, p < 0.002).

"Because of the good visibility, the reduced need to repeat endoscopy, and the confident feeling that the treating physician has seen all parts of the stomach and esophagus and has done what the patient needs, patients can be discharged sooner," Dr. Altraif pointed out.

The need for sclerotherapy was similar in the two groups, however, as were the need for repeat endoscopy and the numbers of units of transfused blood.

No drug-related adverse effects occurred, Dr. Altraif and colleagues report.

Based on these results, Dr. Altraif said, "We routinely give erythromycin to all cirrhotics presenting with bleeding, except those who have contraindications."

He noted that cardiac arrhythmia is the major contraindication to erythromycin use, because it can prolong the Q-T interval.

"There are alternative medicines available, such as pro-kinetics," he continued, "but erythromycin is far more potent, very cheap, well tolerated, it acts quickly and is widely available with little or no side effects in this setting."

He believes that a large, multicenter trial would show other benefits to erythromycin pretreatment in patients with variceal bleeding, including a reduction in transfusion rates, fewer cases of aspiration pneumonia and other complications, and decreased mortality.

SOURCE: http://link.reuters.com/beh42r

Gastrointest Endosc 2010.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.